[1]
P. Kramer, “Dual Blockade of Inhibitory Immunoreceptors TIGIT and PD-1 Produces Optimal Synergistic Anti-Tumor Effects”, MJUSc, vol. 1, no. 1, pp. 3–4, Oct. 2022, doi: 10.17161/mjusc.v1i1.18573.